कंपनी का अवलोकन
Beyond Air, Inc. (XAIR) operates as a commercial-stage entity within the healthcare sector, specifically focusing on the medical devices industry. The company is dedicated to developing the Lungfit platform, which functions as a sophisticated nitric oxide generator and delivery system designed for therapeutic applications. Its operational scope extends across three distinct business segments, including Beyond Air, Beyond Cancer, and NeuroNos, indicating a diversified approach to medical technology solutions. With a market capitalization of $7.91M, annual revenue of $6.92M, and an employee count of 61, the company maintains a relatively small-scale footprint in the broader market. These financial dimensions suggest that Beyond Air, Inc. is an early-to-mid-stage biopharmaceutical firm where current revenue figures reflect initial market penetration rather than mature industry dominance, positioning it as a niche player seeking to establish a foothold in specialized medical treatment markets.
वित्तीय स्वास्थ्य
The company reported trailing twelve-month revenue of $6.92M against a net income of $-31,001,000, while EBITDA stood at $-25,785,000, revealing a significant disparity between top-line sales and bottom-line profitability. This substantial gap between revenue and net income indicates a heavy cost structure driven by research and development expenditures typical of the medical device sector, where high upfront investments are required before commercial viability is achieved. Free cash flow for the period was negative at $-18,648,376, which implies that the company is currently consuming cash reserves to fund operations and growth initiatives rather than generating surplus liquidity for immediate reinvestment or shareholder returns. The gross margin stands at 1.8%, operating margin is negative at -300.6%, and profit margin is 0.0%, collectively highlighting severe cost pressures and the absence of operational profitability at this stage of development. On the balance sheet, total cash holdings of $11.66M are outweighed by total debt of $23.59M, resulting in a debt-to-equity ratio of 284.71, which characterizes the company's financial position as highly leveraged rather than conservative. Despite this leverage, the current ratio of 5.12 suggests that the company maintains strong short-term liquidity, as its current assets significantly exceed its current liabilities. Furthermore, the return on equity is -240.2% and the return on assets is -51.2%, metrics that clearly demonstrate that management has not yet achieved positive capital efficiency or effective wealth generation for shareholders.
मूल्यांकन आकलन
Valuation metrics for Beyond Air, Inc. show a trailing P/E ratio marked as N/A due to lack of profitability, while the forward P/E is recorded at -0.45, reflecting the negative earnings expectation for the upcoming period. The absence of a positive trailing P/E implies that traditional earnings-based valuation models are currently inapplicable, forcing investors to rely on alternative metrics to assess the company's worth. The price-to-book ratio is 0.78, indicating that the market values the company at less than its book value, which often suggests a discount applied to firms with unproven growth potential or high uncertainty regarding future earnings realization. Additionally, the price-to-sales ratio is 1.14 and the EV/EBITDA is -0.78, metrics that suggest the market is pricing the stock based on revenue generation rather than earnings power, a common practice for pre-profitable biotech and medical device firms. Regarding price volatility, the 52-week high is $5.84 and the 52-week low is $0.65, meaning the current trading price sits significantly below the recent peak but remains well above the year's minimum threshold. The beta value of 0.53 indicates that the stock exhibits lower price volatility relative to the broader market, suggesting it may be less sensitive to general market fluctuations than high-beta technology stocks.
Growth & Income
Beyond Air, Inc. achieved a year-over-year revenue growth rate of 104.7%, whereas earnings growth is marked as N/A due to continued losses, implying that top-line expansion is currently outpacing the realization of profitability. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm retains all available earnings to fund its capital-intensive operations and research programs rather than distributing income to shareholders. This reinvestment strategy is standard for companies in the medical device industry that are still navigating the path toward commercialization and regulatory approval for their platforms. Overall, the growth and income profile of Beyond Air, Inc. is characterized by rapid revenue expansion coupled with a complete absence of dividend income, reflecting a business model focused entirely on scaling operations and developing its Lungfit platform for future market capture.